PBM Innovations
Putting Patients at the Center
PBMs are not waiting for government interventions or unnecessary mandates to innovate and adapt to changing market conditions to help patients.
Click on an icon below to learn more
The core mission of pharmacy benefit managers (PBMs) is to reduce drug costs for health plan sponsors and patients.
As drug companies continue to set and increase exorbitant prices for prescription drugs, PBMs are more valuable than ever to patients and payers. Consumers want access to the therapies and health care services that deliver on what Americans need to get and stay healthy, affordably, and conveniently. That’s why employers, unions, health insurers and other health plan sponsors hire PBMs to bring down costs.
As drug companies continue to increase prices, (an average 4% for increases in January 2025, alone), unprecedented demand for drugs is spurring an affordability challenge. The work to lower drug costs and increase affordable access requires the ability to constantly innovate and adapt to changing market conditions. PBMs are not waiting for government interventions or unnecessary mandates to address these market demands. Recently, PBMs across the industry, from big to small, have rolled out new, innovative programs to help plan sponsors tackle high drug costs, allowing patients to access the drugs they need.
Learn More
Pharmacy Innovation Programs
Pharmacy Innovation Programs
PBMs recognize that pharmacies are an important part of patient care across the U.S.
Partnership programs between PBMs and pharmacies provide patients with a higher-quality, lower-cost pharmacy experience. Especially in rural areas, patients may depend on their pharmacist for more than filling prescriptions. PBMs across the industry are partnering with independent pharmacies so they can best serve their patient populations.
Access to GLP-1s for Weight Loss
Glucagon-like peptide 1 (GLP-1) agonists are a class of drugs that are indicated for improving blood sugar levels in type 2 diabetes mellitus, and three prominent GLP-1 drugs are also approved for chronic weight management.
According to one survey, in 2023, 91% of commercial plan sponsors covered GLP-1s for diabetes, while just 33% covered them for weight management. Employers often cite the increased costs of the weight management versions of these drugs as barriers to coverage. PBMs are responding to the evolving GLP-1 drug class to support employers and patients.
Learn More
Access to GLP-1s for Weight Loss
Learn More
Patient Out-of-Pocket Cost Sharing Programs
Patient Out-of-Pocket Cost Sharing Programs
Even as the average cost-sharing payments for patients decline each year, two thirds of insured adults under 65 are worried about affording their prescription drugs. Many of these challenges with cost sharing result from exposure to high drug list prices set by drug companies. When high list prices affect affordability for insured patients, those impacted are less likely to get on and stay on their medication.

PBMs offer employers, unions, and other health plan sponsors novel programs and ideas to help patients affordably access their prescriptions.
Biosimilar Access
Biosimilars — biological drugs with no meaningful differences from FDA-approved reference biological products — offer patients opportunities for safe, effective, low-cost alternatives to expensive biologics.
PBMs are working with employers and other health plan sponsors to break down the barriers surrounding biosimilars and make them more accessible and affordable.
Learn More
Biosimilar Access
Learn More
Patient Transparency Tools
Patient Transparency Tools
Tools that provide transparency facilitate convenient access to information that empowers patients.
Educating patients leads to more informed choices and better savings opportunities. Technological innovations help patients access the right information at the right time, helping them live well: